CA2974998C - Chimeric antigen receptors - Google Patents

Chimeric antigen receptors Download PDF

Info

Publication number
CA2974998C
CA2974998C CA2974998A CA2974998A CA2974998C CA 2974998 C CA2974998 C CA 2974998C CA 2974998 A CA2974998 A CA 2974998A CA 2974998 A CA2974998 A CA 2974998A CA 2974998 C CA2974998 C CA 2974998C
Authority
CA
Canada
Prior art keywords
car
domain
cells
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2974998A
Other languages
English (en)
French (fr)
Other versions
CA2974998A1 (en
Inventor
Shinya Tanaka
Naoto Hirano
Yuki KAGOYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Takara Bio Inc
Original Assignee
University Health Network
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Takara Bio Inc filed Critical University Health Network
Publication of CA2974998A1 publication Critical patent/CA2974998A1/en
Application granted granted Critical
Publication of CA2974998C publication Critical patent/CA2974998C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
CA2974998A 2015-02-12 2016-02-11 Chimeric antigen receptors Active CA2974998C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115527P 2015-02-12 2015-02-12
US62/115,527 2015-02-12
PCT/CA2016/050126 WO2016127257A1 (en) 2015-02-12 2016-02-11 Chimeric antigen receptors

Publications (2)

Publication Number Publication Date
CA2974998A1 CA2974998A1 (en) 2016-08-18
CA2974998C true CA2974998C (en) 2022-04-26

Family

ID=56614021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974998A Active CA2974998C (en) 2015-02-12 2016-02-11 Chimeric antigen receptors

Country Status (7)

Country Link
US (2) US10336810B2 (enExample)
EP (1) EP3256496B1 (enExample)
JP (2) JP6846352B2 (enExample)
KR (1) KR102607152B1 (enExample)
CA (1) CA2974998C (enExample)
ES (1) ES2857998T3 (enExample)
WO (1) WO2016127257A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256496B1 (en) 2015-02-12 2020-12-30 University Health Network Chimeric antigen receptors
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
JP7178906B2 (ja) * 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性T細胞の活性を強化するためのプラットフォームである、その受容体IL-2Rβに繋ぎ止められたインターロイキン-2
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール2 セラピューティクス インク. 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法
CN109996811A (zh) 2016-08-03 2019-07-09 约翰·F·迪帕西奥 用于用嵌合抗原受体治疗t细胞恶性肿瘤的car-t细胞的基因编辑
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7206214B2 (ja) * 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
IL317065A (en) * 2018-03-02 2025-01-01 Allogene Therapeutics Inc Chimeric inducible cytokine receptors
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
SG11202007874XA (en) 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Rapamycin resistant cells
EP3784272A1 (en) * 2018-04-27 2021-03-03 CRISPR Therapeutics AG Anti-bcma car-t-cells for plasma cell depletion
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
US20210252069A1 (en) * 2018-09-05 2021-08-19 Seogkyoung KONG Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor
WO2020172643A2 (en) * 2019-02-21 2020-08-27 Luk John M Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
MX2021010443A (es) 2019-03-01 2021-12-10 Allogene Therapeutics Inc Receptores de citocinas quimericos constitutivamente activos.
AU2020232216B2 (en) 2019-03-01 2025-09-25 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
GB201911187D0 (en) * 2019-08-05 2019-09-18 Autolus Ltd Receptor
GB201912515D0 (en) * 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
AU2020342544A1 (en) * 2019-09-05 2022-03-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN110717956B (zh) * 2019-09-30 2023-06-20 重庆大学 一种有限角投影超像素引导的l0范数最优化重建方法
TWI717880B (zh) * 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CN115038453A (zh) * 2020-01-14 2022-09-09 辛德凯因股份有限公司 具有改变的icd stat信号转导的cd122
EP4090383A4 (en) * 2020-01-14 2024-01-24 Synthekine, Inc. IL2 ORTHOLOGIST AND APPLICATION METHOD
CA3167065A1 (en) 2020-02-24 2021-09-02 Regina Junhui LIN Bcma car-t cells with enhanced activities
GB2609103A (en) * 2020-02-25 2023-01-25 Quell Therapeutics Ltd Chimeric receptors for use in engineered cells
US20230121433A1 (en) * 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
EP4135726A4 (en) * 2020-04-17 2024-09-25 The Council of the Queensland Institute of Medical Research IMMUNE CELLS WITH IMPROVED FUNCTION
US20230167191A1 (en) * 2020-04-24 2023-06-01 Sorrento Therapeutics, Inc. Memory Dimeric Antigen Receptors (mDARs)
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN116782937A (zh) 2020-12-10 2023-09-19 优特力克斯有限公司 抗pd-1抗体及其用途
CN114716548B (zh) 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN113512125B (zh) * 2021-04-26 2024-01-19 北京双赢科创生物科技有限公司 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞
CN118251410A (zh) 2021-09-17 2024-06-25 帕克癌症免疫治疗研究所 使用il-9信号传导结构域的开关受体
WO2023158997A2 (en) * 2022-02-15 2023-08-24 Memorial Sloan-Kettering Cancer Center Compositions including killer innate-like t cells and uses therof
US20250154463A1 (en) * 2022-02-15 2025-05-15 Memorial Sloan-Kettering Cancer Center Compositions including cytotoxic innate lymphoid cells and uses thereof
AU2023307698A1 (en) * 2022-07-11 2025-01-23 The Board Of Trustees Of The Leland Stanford Junior University Tunable cytokine receptor signaling domains
KR20240016216A (ko) 2022-07-26 2024-02-06 (주)에임드바이오 항-ror1 항체 및 이의 용도
EP4342907A1 (en) 2022-09-21 2024-03-27 AvenCell Europe GmbH Switchable chimeric antigen receptors and their use
JP2025532948A (ja) 2022-09-30 2025-10-03 カリブー・バイオサイエンシーズ・インコーポレイテッド 抗ror1キメラ抗原受容体(car)、carを発現する細胞、及び関連する方法
EP4633648A1 (en) * 2022-12-15 2025-10-22 Carisma Therapeutics Inc. Chimeric antigen receptors including jak/stat binding domains and modified immune cells
WO2025096673A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising cells targeting cancer and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CA2751762A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
WO2012154858A1 (en) 2011-05-09 2012-11-15 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
EP3256496B1 (en) 2015-02-12 2020-12-30 University Health Network Chimeric antigen receptors

Also Published As

Publication number Publication date
JP2018509893A (ja) 2018-04-12
US10822392B2 (en) 2020-11-03
US20190359685A1 (en) 2019-11-28
CA2974998A1 (en) 2016-08-18
EP3256496A1 (en) 2017-12-20
ES2857998T3 (es) 2021-09-29
KR102607152B1 (ko) 2023-11-27
EP3256496B1 (en) 2020-12-30
EP3256496A4 (en) 2018-12-12
US10336810B2 (en) 2019-07-02
JP2021036883A (ja) 2021-03-11
KR20170116084A (ko) 2017-10-18
WO2016127257A1 (en) 2016-08-18
JP6846352B2 (ja) 2021-03-24
US20180037630A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
US10822392B2 (en) Nucleic acids comprising polynucleotides encoding chimeric antigen receptors
AU2019308290B2 (en) Chimeric antigen receptors with BCMA specificity and uses thereof
CN108884164B (zh) 用于免疫疗法的经修饰细胞
AU2016313082B2 (en) Chimeric antigen receptors with integrated controllable functions
KR20220124173A (ko) Lilrb1-기반 키메라 항원 수용체
KR20230051602A (ko) Icos 리간드 변이체 면역조절 단백질 및 그의 용도
KR20230007559A (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
CN110511912B (zh) 免疫细胞的功能调节
US12351618B2 (en) Engineered trimeric CD70 proteins and uses thereof
US20220281994A1 (en) Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof
JP2022512475A (ja) 二量体化剤調節免疫受容体複合体
US20230192848A1 (en) Engineered cell compositions and methods of use thereof
CN111655720A (zh) Nkg2d daric受体
AU2021318297A1 (en) Immune Synapse-Stabilizing Chimeric Antigen Receptor (CAR) T Cell
US20220267420A1 (en) Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
CN116490518A (zh) 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
US20250121002A1 (en) ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
HK40058918B (zh) A2/ny-eso-1特异性t细胞受体及其用途
JP2025540251A (ja) 血液癌の治療において使用するためのキット
KR20240069766A (ko) Il5ra 세포 표면 마커
KR20230033097A (ko) 기능이 강화된 신규 키메라 항원 수용체(car)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201218